Kiniksa Pharmaceuticals International (KNSA) FY2025 10-K Risk Factors: 12 New, 18 Dropped

What the changes say

US ARCALYST remains the revenue base, while international expansion now carries explicit approval and commercialization uncertainty.
Clinical candidates face clearer warnings about trial delays, immune-system safety findings, and unreliable interim data.
Policy risks now highlight IRA Medicare changes, tariffs, GDPR fines, and geopolitical threats to patents.

What changed since the prior 10-K

New

NewRisks Related to Commercialization
Any future growth outside of the United States would be subject to additional regulatory burdens and other risks and uncertainties
Expansion beyond the United States may require additional approvals, including for programs involving Huadong and access programs.
NewRisks Related to Product Development
If we do not accomplish one or more of these factors in a timely manner or at all we could experience significant delays in, or an inability to, timely or successfully commercialize our product candidates
Delays, failed safety or efficacy results, or regulatory refusals could prevent timely commercialization of product candidates.
NewRisks Related to Product Development
Undesirable side effects or adverse reactions caused by any of our product candidates may be identified that could delay or prevent their marketing approval or limit their use
Immune-system effects, including serious infections or malignancy, could halt trials, delay approval, or restrict product labels.
NewRisks Related to Product Development
Interim, preliminary and “top-line” data from our clinical trials may differ from final data
Interim or topline trial results may materially change after enrollment, treatment, audits, or final data analysis.
NewRisks Related to Marketing Approval and Regulatory Matters
If we obtain marketing authorization of our current or future product candidates in a major pharmaceutical market, we may not seek or obtain approval or commercialize our current products or product candidates in other markets, which would limit our ability to realize their full market potential
Approval in one country may not support approval elsewhere, requiring costly additional studies and delaying ARCALYST or candidate launches.
NewRisks Related to Competition, Executing our Strategy and Managing Growth
If any of these events occurs, we may not be successful in executing our growth strategy. Our growth strategy or strategic transactions may not deliver the anticipated results or we may need to spend significant resources to refine or otherwise alter our strategy
Acquisitions, collaborations, or other strategic transactions could create integration problems, liabilities, debt, dilution, or unexpected costs.
NewRisks Related to Intellectual Property
Class A ordinary shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities
Patent litigation or other intellectual-property proceedings could consume resources and weaken Kiniksa’s ability to compete.
NewRisks Related to Intellectual Property
decisions by courts in the United States and other countries may affect the ability to obtain and enforce adequate intellectual property protection for our technology
Foreign legal changes, including Russia’s ability to exploit certain U.S.-owned inventions without compensation, could weaken patent protection.
NewRisks Related to Intellectual Property
In the United States, the UK, the EU and other jurisdictions, there have been and we expect there will continue to be a number of executive, legislative and regulatory initiatives and proposed changes to healthcare systems, drug pricing and reimbursement policies that could affect our operations
The IRA and other healthcare reforms could change Medicare pricing, rebates, out-of-pocket costs, discounts, and negotiations.
NewRisks Related to Intellectual Property
Healthcare reform efforts have been and may continue to be subject to scrutiny, legal challenge and subsequent amendment, creating further uncertainty
Healthcare reforms, drug tariffs, Medicare spending cuts, taxes, and legal challenges could reduce profitability or delay commercial success.
NewRisks Related to Intellectual Property
reasonable and appropriate in light of the sensitivity and volume of consumer information held by the company, the size and complexity of its business and the cost to improve security and reduce vulnerabilities
GDPR and other international privacy rules could impose costly compliance obligations, investigations, claims, processing restrictions, or fines up to €20 million or 4% of global revenue.
NewRisks Related to Intellectual Property
Changes in United States trade policy, including tariffs imposed by the United States and any reciprocal tariffs imposed in response, could materially impact our business and results of operations
U.S. and reciprocal tariffs could raise costs for imported pharmaceutical products, components, and materials used in ARCALYST operations.

Dropped

DroppedRisks Related to Commercialization
small discounts, if aggregated across payors, may cause materially lower revenue generation in the long-term, which may offset the increased revenue we hoped to realize through a price increase
DroppedRisks Related to Commercialization
Our future growth may depend, in part, on our ability to commercialize our current and future products in markets outside of the United States either on our own or through collaborations with third parties
DroppedRisks Related to Product Development
Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, time consuming and uncertain as to the outcome
DroppedRisks Related to Product Development
Our products and product candidates modulate the immune system and carry risks associated with immunosuppression, including the risk of serious infections and other potential serious health risks
Payor discounts could reduce long-term revenue and trigger similar concessions from other payors or territories.
DroppedRisks Related to Product Development
Any of these events could prevent us from achieving or maintaining market acceptance of the particular product or product candidate, if approved, and could significantly harm our business, results of operations and prospects
DroppedRisks Related to Marketing Approval and Regulatory Matters
2025 change in presidential administration, which may render our clinical data, biologic manufacturing process and other supporting information insufficient for approval or restrict us from marketing our product candidates in the manner in which we anticipate
DroppedRisks Related to Manufacturing and Our Reliance on Third Parties
adequately meet patient demand for ARCALYST or may be required to effect a recall, any of which would adversely affect our business, results of operations and financial condition
International commercialization through Kiniksa, collaborators, or Huadong could be difficult.
DroppedRisks Related to Manufacturing and Our Reliance on Third Parties
generally met our demand on a timely basis in the past, they may subordinate our needs in the future to their other customers
DroppedRisks Related to Manufacturing and Our Reliance on Third Parties
clinical trials on a government-sponsored database within certain timeframes. Failure to do so when required can result in fines, adverse publicity and civil and criminal sanctions
DroppedRisks Related to Competition, Executing our Strategy and Managing Growth
We need to continue to develop our company and expand our scope of operations, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations
Clinical trials may be delayed, conducted differently than planned, or never completed.
DroppedRisks Related to Intellectual Property
vary on a country-by-country basis depending on the jurisdiction in which a product candidate is approved and the particular regulatory exclusivity for which the product is eligible as of the time of approval in such jurisdiction
DroppedRisks Related to Intellectual Property
or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights cannot be predicted with any certainty
Immune-system modulation could cause serious infections or other health risks and halt trials.
DroppedRisks Related to Intellectual Property
We have not yet registered trademarks for a commercial trade name for our product candidates in the United States or jurisdictions outside of the United States and failure to secure such registrations could adversely affect our business
Interim or topline trial data could change materially after additional data and analysis.
DroppedRisks Related to Intellectual Property
required to relinquish rights to our product candidates or products. Any of these occurrences could materially affect our business, financial condition and results of operations
A change in presidential administration could affect approval standards, indications, patient populations, pricing, or postmarketing requirements.
DroppedRisks Related to Intellectual Property
Enacted and future healthcare legislation may have a material adverse effect on our business and results of operations
DroppedRisks Related to Intellectual Property
The increasing and evolving focus on environmental, social and governance (“ESG”) matters could increase our costs, harm our reputation, adversely impact our access to capital and financial results or otherwise adversely impact our business
DroppedRisks Related to Ownership of Our Ordinary Shares
transfer, a substantial amount of their ordinary shares (after certain restrictions on conversion or resale lapse), the market price of our Class A ordinary shares could decline
Regeneron’s ARCALYST manufacturing capacity may be insufficient, causing shortages, lost material, or recalls.
DroppedRisks Related to Our Jurisdiction of Incorporation and Certain Tax Risks
We may encounter unforeseen costs following the Redomiciliation and may not realize meaningful benefits

Reworded

94% rewrittenRisks Related to Intellectual Property
Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations and financial condition
The risk now states that Kiniksa is currently subject to privacy obligations, rather than merely potentially becoming subject to them; the substance is otherwise similar.
91% rewrittenRisks Related to Intellectual Property
Further, our financial results may fluctuate significantly from quarter-to-quarter and year-to-year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. Corporate profitability may not be sustained in subsequent periods
The funding risk now expressly adds that Kiniksa may need to relinquish rights to products or candidates if financing fails.
87% rewrittenRisks Related to Intellectual Property
We may not be able to effectively enforce our intellectual property rights throughout the world
The revised text more specifically highlights foreign legal systems that may disfavor enforcement by U.S.-based companies.
84% rewrittenRisks Related to Commercialization
It may be difficult for us to realize the benefit of increasing the price of certain of our commercialized products
The text is substantively unchanged: payor responses to ARCALYST price increases could require concessions or reduce coverage.
84% rewrittenRisks Related to Intellectual Property
important to our business. We also rely on trade secrets, proprietary know-how and continuing technological innovation to develop and maintain our proprietary or intellectual property position
The wording changes from separately describing owned and licensed rights to stating that Kiniksa both owns and licenses them.
Was: also rely on trade secrets, proprietary know-how and continuing technological innovation to develop and maintain our proprietary or intellectual property position
83% rewrittenRisks Related to Commercialization
Our business and operations are subject to extensive healthcare regulation and enforcement by various government entities, and our failure to strictly adhere to these regulatory requirements could have a detrimental impact on our business
The revised text replaces the broad healthcare-law challenge discussion with detailed obligations covering manufacturing, promotion, reporting, and postmarketing activities.
Was: Our business operations are subject to extensive healthcare regulation and enforcement by various government entities, and our failure to strictly adhere to these regulatory requirements could have a detrimental impact on our business
82% rewrittenRisks Related to Marketing Approval and Regulatory Matters
Our products, current product candidates and any of our future product candidates regulated as biologics in the United States may face biosimilar competition sooner than anticipated
The text is substantively unchanged and continues to describe the BPCIA’s four-year filing and 12-year approval limits for biosimilars.
78% rewrittenRisks Related to Manufacturing and Our Reliance on Third Parties
The third parties upon whom we rely for the supply of our products and product candidates are our sole source of supply, and the loss of any of these suppliers could significantly harm our business or the business of our partners
The text is substantively unchanged, continuing to identify single-source or limited-source suppliers and Samsung’s planned ARCALYST role.
76% rewrittenRisks Related to Marketing Approval and Regulatory Matters
We face substantial uncertainty regarding potential regulatory developments in the United States that may adversely affect our business
Was: Due to the recent change in presidential administration, we face substantial uncertainty regarding potential regulatory developments in the United States that may adversely affect our business
69% rewrittenRisks Related to Intellectual Property
We have a history of operating losses and may require substantial additional financing in the future
69% rewrittenRisks Related to Our Jurisdiction of Incorporation and Certain Tax Risks
As a result of increased shareholder voting requirements in the UK relative to the United States, we will have less flexibility with respect to our ability to issue new shares
Was: As a result of increased shareholder voting requirements in the United Kingdom relative to Bermuda, we will have less flexibility with respect to our ability to issue new shares
66% rewrittenRisks Related to Competition, Executing our Strategy and Managing Growth
We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do
64% rewrittenRisks Related to Ownership of Our Ordinary Shares
The price of our Class A ordinary shares may be volatile and fluctuate substantially, which could result in substantial losses for holders of our Class A ordinary shares
62% rewrittenRisks Related to Ownership of Our Ordinary Shares
Sales of a number of our Class A ordinary shares in the public market, including Class A ordinary shares issuable upon conversion of our Class B, Class A1 and Class B1 ordinary shares, could cause the share price of our Class A ordinary shares to fall
60% rewrittenRisks Related to Commercialization
We rely on a select network of third party specialty pharmacies to market and sell ARCALYST that may not meet our or our patients’ needs
59% rewrittenRisks Related to Manufacturing and Our Reliance on Third Parties
Our business involves the use of hazardous materials, and we and our third party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business
58% rewrittenRisks Related to Intellectual Property
Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities
57% rewrittenRisks Related to Intellectual Property
If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed
52% rewrittenRisks Related to Product Development
We may find it difficult to enroll participants in our clinical trials in a timely manner given the limited number of patients who have the diseases for which our product candidates are being studied, our particular enrollment criteria or competing clinical studies in the same patient population
49% rewrittenRisks Related to Manufacturing and Our Reliance on Third Parties
We are conducting a technology transfer with respect to the manufacturing process of ARCALYST drug substance from Regeneron to Samsung and the analytical testing methods of ARCALYST drug substance and drug product to new CTLs. Such technology transfer will be subject to significant risks and uncertainties
42% rewrittenRisks Related to Our Jurisdiction of Incorporation and Certain Tax Risks
Investors in the United States may find it difficult to enforce their civil liabilities against us
42% rewrittenRisks Related to Product Development
If we are unable to advance our product candidates in clinical development and obtain regulatory approval, or experience significant delays in doing so, our business may be significantly harmed
36% rewrittenRisks Related to Intellectual Property
Unfavorable global economic or operational conditions could adversely affect our business, financial condition or results of operations
35% rewrittenRisks Related to Our Jurisdiction of Incorporation and Certain Tax Risks
Our parent company is organized under the laws of England and Wales. The rights of holders of our ordinary shares are governed by English law and our articles of association, and these may not provide the same rights as shares offered by American companies
Was: Our parent company is organized under the laws of England and Wales. The rights of holders of our ordinary shares are governed by English law and our articles of association, and these may not provide the same rights as shares offered by American or Bermudan companies
32% rewrittenRisks Related to Commercialization
Evolving health policy and associated legislative changes related to coverage and reimbursement aimed at lowering healthcare expenditures could impact the commercialization of our product candidates. Pharmaceutical pricing has been, and likely will continue to be, a central component of these efforts
27% rewrittenRisks Related to Commercialization
We may not be able to continue to commercialize ARCALYST or be successful in commercializing any future products, potentially impairing the commercial potential for our current and future products to generate any revenue
27% rewrittenRisks Related to Intellectual Property
Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
24% rewrittenRisks Related to Our Jurisdiction of Incorporation and Certain Tax Risks
We may be treated as a passive foreign investment company (“PFIC”) for United States federal income tax purposes. If we were to be classified a PFIC, this could result in adverse United States federal income tax consequences to United States Holders
24% rewrittenRisks Related to Intellectual Property
Our employees, principal investigators, CROs, consultants and other third party service providers may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading
24% rewrittenRisks Related to Intellectual Property
Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product or our current or future product candidates
22% rewrittenRisks Related to Commercialization
Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of ARCALYST and any product candidates that we may develop, if approved
22% rewrittenRisks Related to Intellectual Property
Our future success depends on our ability to retain key executives and senior management; attract, retain and motivate qualified personnel; and implement succession planning efforts to ensure our long-term success

All 54 risk factors

Headings as the filing states them, in filing order.

Risks Related to Commercialization

01We may not be able to continue to commercialize ARCALYST or be successful in commercializing any future products, potentially impairing the commercial potential for our current and future products to generate any revenue27% rewritten
02We rely on a select network of third party specialty pharmacies to market and sell ARCALYST that may not meet our or our patients’ needs60% rewritten
03It may be difficult for us to realize the benefit of increasing the price of certain of our commercialized products84% rewritten
04Evolving health policy and associated legislative changes related to coverage and reimbursement aimed at lowering healthcare expenditures could impact the commercialization of our product candidates. Pharmaceutical pricing has been, and likely will continue to be, a central component of these efforts32% rewritten
05Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of ARCALYST and any product candidates that we may develop, if approved22% rewritten
06Any future growth outside of the United States would be subject to additional regulatory burdens and other risks and uncertaintiesNew
07Our business and operations are subject to extensive healthcare regulation and enforcement by various government entities, and our failure to strictly adhere to these regulatory requirements could have a detrimental impact on our business83% rewritten

Risks Related to Product Development

08If we are unable to advance our product candidates in clinical development and obtain regulatory approval, or experience significant delays in doing so, our business may be significantly harmed42% rewritten
09If we do not accomplish one or more of these factors in a timely manner or at all we could experience significant delays in, or an inability to, timely or successfully commercialize our product candidatesNew
10We may find it difficult to enroll participants in our clinical trials in a timely manner given the limited number of patients who have the diseases for which our product candidates are being studied, our particular enrollment criteria or competing clinical studies in the same patient population52% rewritten
11Undesirable side effects or adverse reactions caused by any of our product candidates may be identified that could delay or prevent their marketing approval or limit their useNew
12Interim, preliminary and “top-line” data from our clinical trials may differ from final dataNew

Risks Related to Marketing Approval and Regulatory Matters

13Our products, current product candidates and any of our future product candidates regulated as biologics in the United States may face biosimilar competition sooner than anticipated82% rewritten
14If we obtain marketing authorization of our current or future product candidates in a major pharmaceutical market, we may not seek or obtain approval or commercialize our current products or product candidates in other markets, which would limit our ability to realize their full market potentialNew
15We face substantial uncertainty regarding potential regulatory developments in the United States that may adversely affect our business76% rewritten

Risks Related to Manufacturing and Our Reliance on Third Parties

16We are conducting a technology transfer with respect to the manufacturing process of ARCALYST drug substance from Regeneron to Samsung and the analytical testing methods of ARCALYST drug substance and drug product to new CTLs. Such technology transfer will be subject to significant risks and uncertainties49% rewritten
17The third parties upon whom we rely for the supply of our products and product candidates are our sole source of supply, and the loss of any of these suppliers could significantly harm our business or the business of our partners78% rewritten
18Our business involves the use of hazardous materials, and we and our third party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business59% rewritten

Risks Related to Competition, Executing our Strategy and Managing Growth

19We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do66% rewritten
20If any of these events occurs, we may not be successful in executing our growth strategy. Our growth strategy or strategic transactions may not deliver the anticipated results or we may need to spend significant resources to refine or otherwise alter our strategyNew

Risks Related to Intellectual Property

21important to our business. We also rely on trade secrets, proprietary know-how and continuing technological innovation to develop and maintain our proprietary or intellectual property position84% rewritten
22Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business27% rewritten
23We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights
24Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities58% rewritten
25Class A ordinary shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activitiesNew
26Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
27We may not be able to effectively enforce our intellectual property rights throughout the world87% rewritten
28decisions by courts in the United States and other countries may affect the ability to obtain and enforce adequate intellectual property protection for our technologyNew
29Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product or our current or future product candidates24% rewritten
30If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed57% rewritten
31If our trademarks and trade names are not adequately protected, then we may be unable to build name recognition in our markets of interest and our business may be adversely affected
32We have a history of operating losses and may require substantial additional financing in the future69% rewritten
33Further, our financial results may fluctuate significantly from quarter-to-quarter and year-to-year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. Corporate profitability may not be sustained in subsequent periods91% rewritten
34In the United States, the UK, the EU and other jurisdictions, there have been and we expect there will continue to be a number of executive, legislative and regulatory initiatives and proposed changes to healthcare systems, drug pricing and reimbursement policies that could affect our operationsNew
35Healthcare reform efforts have been and may continue to be subject to scrutiny, legal challenge and subsequent amendment, creating further uncertaintyNew
36Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations and financial condition94% rewritten
37reasonable and appropriate in light of the sensitivity and volume of consumer information held by the company, the size and complexity of its business and the cost to improve security and reduce vulnerabilitiesNew
38Our future success depends on our ability to retain key executives and senior management; attract, retain and motivate qualified personnel; and implement succession planning efforts to ensure our long-term success22% rewritten
39Our employees, principal investigators, CROs, consultants and other third party service providers may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading24% rewritten
40Changes in United States trade policy, including tariffs imposed by the United States and any reciprocal tariffs imposed in response, could materially impact our business and results of operationsNew
41Unfavorable global economic or operational conditions could adversely affect our business, financial condition or results of operations36% rewritten
42Climate change, and related regulation, may result in increased costs or otherwise negatively impact our operations and harm our business

Risks Related to Ownership of Our Ordinary Shares

43The price of our Class A ordinary shares may be volatile and fluctuate substantially, which could result in substantial losses for holders of our Class A ordinary shares64% rewritten
44If securities or industry analysts cease publishing about us or publish unfavorable research or reports about us, our business or our market, our share price and trading volume could decline
45Sales of a number of our Class A ordinary shares in the public market, including Class A ordinary shares issuable upon conversion of our Class B, Class A1 and Class B1 ordinary shares, could cause the share price of our Class A ordinary shares to fall62% rewritten
46We have anti-takeover provisions in our articles of association that may discourage a change of control
47Because we do not anticipate paying any cash dividends on our shares in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our shareholders

Risks Related to Our Jurisdiction of Incorporation and Certain Tax Risks

48As a result of increased shareholder voting requirements in the UK relative to the United States, we will have less flexibility with respect to our ability to issue new shares69% rewritten
49Our parent company is organized under the laws of England and Wales. The rights of holders of our ordinary shares are governed by English law and our articles of association, and these may not provide the same rights as shares offered by American companies35% rewritten
50Investors in the United States may find it difficult to enforce their civil liabilities against us42% rewritten
51We may become subject to unanticipated tax liabilities, including liabilities arising from the reallocation of our taxable income among our subsidiaries
52Changes and uncertainties in the tax system in the countries in which we have operations, could materially adversely affect our financial condition and results of operations, and reduce net returns to our shareholders
53We may be treated as a passive foreign investment company (“PFIC”) for United States federal income tax purposes. If we were to be classified a PFIC, this could result in adverse United States federal income tax consequences to United States Holders24% rewritten
54If a United States Holder is treated as owning at least 10% of our shares, by vote or by value, such holder may be subject to adverse United States federal income tax consequences

Other Kiniksa Pharmaceuticals International 10-Ks

FY2024 10-K risk factors
60 risks
Single-product commercialization reliance on ARCALYST drives primary risks, including sole-source manufacturing dependencies and complex intellectual property protection.
Filed Feb 25, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.